ReviewOncoscience2025
Prognostic significance of trophoblastic differentiation and β-hCG secretion in somatic malignancies of uterine corpus: A systematic review with survival analysis.
Review in Oncoscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Selection Based on Dominant Tumor Biology in Endometrial Carcinoma with Choriocarcinomatous Differentiation: A Case-Based Review.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrophoblastic differentiation or beta-human chorionic gonadotropin (β-hCG) secretion in endometrial carcinoma has been associated with poorly differentiated and aggressive tumors; however, the evidence is largely inconclusive. The review aimed to explore the prognostic role of trophoblastic differentiation and β-hCG in non-trophoblastic, primary uterine corpus cancers. METHODOLOGY: A comprehensive electronic search across databases was conducted for all cases of cancers of the uterine corpus that were either associated with elevated levels of β-hCG or showed evidence of trophoblastic differentiation upon microscopy or both. Cases of gestational choriocarcinoma, trophoblastic tumors, tumors other than uterine corpus, and those tumors of uterine corpus but not reporting β-hCG as a marker were excluded. Data regarding patients' clinic-demographic details, tumor characteristics, β-hCG levels at the time of presentation, and how these values change with treatment, its peak levels, the extent of loco-regional metastasis, details of treatment received, and case fatality were extracted and analysed statistically.
resultsA total of 35 case reports/case series with a total of 40 cases were included in the present review. The mean age at presentation was 57.75 ± 17.22 years. Nulliparity, obesity, hypertension, and diabetes were important risk factors. Post-menopausal or abnormal uterine bleeding was the commonest presenting complaint. Trophoblastic differentiation or β-hCG expression was found to be associated with high tumor grade, poor differentiation, and poor overall patient survival. The lung was the most common site of metastasis.
conclusionsTrophoblastic differentiation or elaboration of β-hCG in cancers of the uterine corpus is a rarity, and the majority of them are associated with a grim prognosis, secondary to being associated with poor differentiation, early hematogenous dissemination, and resistance to chemo-radiotherapy. Measurement of pre-operative β-hCG may be considered in all cases of endometrial carcinomas and sarcomas, and if found elevated, immunohistochemical examination with β-hCG should be carried out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.